Global Influenza Vaccines and Therapeutics Demand is Anticipated to Surpass $12 billion by 2030, Mainly Driven by Seasonal Flu Outbreaks and Gov Immunization Programs
The latest version of the report from Industry Experts Inc, on “Influenza Market,” is unveiled. According to this new market research report, the global Influenza market size is estimated at US$9.6 billion in 2024 and expected to register a CAGR of 4.5% between 2024 and 2030 to reach US$12.4 billion in 2030.
The influenza market is driven by global health initiatives, seasonal outbreaks of flu, and the need for preventive healthcare, leading to a steady demand for vaccines and antiviral treatments. Government immunization programs, increasing awareness, and ongoing R&D investments in vaccine innovation and pandemic preparedness are major market growth factors. Advancements in vaccine technology, such as recombinant and cell-based formulations, have improved the effectiveness and availability of vaccine agents.
In 2024, the oseltamivir phosphate segment led the market with a 47.4% share thanks to its strong effectiveness, broad activity against influenza A & B, and broad availability. As a neuraminidase inhibitor, it blocks viral replication, which reduces symptom severity and duration when taken early. The medication is primarily recommended for treatment and prevention, which enhances its market leadership. Continued research and development efforts focused on new formulations further drive this market growth.
The market for influenza analyzed in this report on a global basis covering all major regions including North America (The United States, Canada, and Mexico), Europe (Germany, France, the United Kingdom, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific), South America (Brazil, Argentina, and Rest of South America) and Rest of World.
The study analyzes the global market trends and outlook for influenza with respect to Product – Vaccines (Quadrivalent and Trivalent), Therapeutics (Oseltamivir Phosphate, Zanamivir, Peramivir, Baloxavir Marboxil and Others [Including Amantadine, Rimantadine, and Emerging Drugs]); Age Group – Pediatrics and Adults; Route of Administration – Injection, Oral and Nasal Spray; Technology - Egg-based Manufacturing, Cell-based Manufacturing and Recombinant DNA Technology; and Distribution Channel – Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels [Including Online Pharmacies, Private Clinics, Specialty Healthcare Centers, and others].
About Industry Experts, Inc
Industry Experts, Inc., ranks among the leading market research providers globally. The company's off-the-shelf and customized business intelligence reports offer strategic insights and valuable guidance to enable various stakeholders, such as corporate strategists, analysts, researchers and startups, among others, in obtaining valuable, crisp and unbiased current and future market data. For more information, contact us on +1-320-497-3787 or visit https://industry-experts.com/
Comments
Post a Comment